Gyre Therapeutics, Inc.GYRENASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank57
5Y CAGR-7.7%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-7.7%/yr
Long-term compound
Percentile
P57
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
3 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 13.92% |
| 2024 | -12.74% |
| 2023 | -17.42% |
| 2022 | -74.16% |
| 2021 | 21.90% |
| 2020 | 20.78% |
| 2019 | 104.24% |
| 2018 | 67.15% |
| 2017 | 11.18% |
| 2016 | 93.94% |